Searched for: subject:"Tumor%5C%2BCells%2C%5C%2BCultured"
(1 - 3 of 3)
document
Meijer, C. (author), Timmer, A. (author), de Vries, E.G.E. (author), Groten, J.P. (author), Knol, A. (author), Zwart, N. (author), Dam, W.A. (author), Sleijfer, D.Th. (author), Mulder, N.H. (author)
Cisplatin (CDDP) is an extremely active drug in the treatment of germ- cell tumours. Earlier, we found an unexpected inverse correlation between the total amount of sulfhydryl groups and CDDP sensitivity in a panel of 3 human germ-cell tumour and 3 colon-carcinoma cell lines. Major components of the sulfhydryl groups are glutathione and...
article 2000
document
Mulder, M. (author), Lombardi, P. (author), Jansen, H. (author), van Berkel, T.J.C. (author), Frants, R.R. (author), Havekes, L.M. (author), Gaubius Instituut TNO (author)
It has previously been shown that lipoprotein lipase (LPL) enhances the binding of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) to HepG2 cells and fibroblasts, up to 80-fold. This increase in binding is LDL receptor-independent and is due to a bridging of LPL between extracellular heparan sulfate proteoglycans (HSPG)...
article 1993
document
Mulder, M. (author), de Wit, E. (author), Havekes, L.M. (author), Gaubius Instituut TNO (author)
It has been suggested that besides the LDL-receptor, hepatocytes possess an apo E or remnant receptor. To evaluate which hepatic lipoprotein receptor is involved in VLDL remnant catabolism, we studied the binding of VLDL remnants to HepG2 cells. Native VLDL was obtained from type IIb hyperlipidemic patients and treated with bovine milk...
article 1991